固肾解毒汤联合西医常规治疗终末期肾病临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R692.5

基金项目:


Clinical Study on Gushen Jiedu Decoction Combined with Conventional Western Medicine Therapy for Hemodialysis Patients with End-Stage Renal Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察固肾解毒汤联合西医常规治疗终末期肾病血液透析患者的临床疗效。方法:选择 110 例终末期肾病血液透析患者为研究对象,按随机数字表法分为研究组和对照组各55 例。对照组给予常规 西医治疗,研究组在对照组基础上给予固肾解毒汤治疗。2 组疗程均为3 个月。评价2 组临床疗效,比较2 组 中医证候评分、肾功能、微炎症反应及预后情况。结果:研究组总有效率为89.09%,对照组为74.55%,2 组 比较,差异有统计学意义(P<0.05)。治疗后,2 组各项中医证候评分均较治疗前降低(P<0.05),且研究组 各项中医证候评分均低于对照组(P<0.05)。治疗后,2 组血肌酐(SCr)、尿素氮(BUN) 指标均较治疗前降 低(P<0.05),且研究组SCr、BUN 指标均低于对照组(P<0.05)。治疗后,2 组血清白细胞介素-6(IL-6)、 肿瘤坏死因子-α (TNF-α) 水平均较治疗前降低(P<0.05),且研究组血清IL-6、TNF-α 水平均低于对照 组(P<0.05)。研究组1 年生存率为87.76%,病死率为12.24%;对照组1 年生存率为70.73%,病死率为 29.27%。2 组1 年生存率和病死率比较,差异有统计学意义(P<0.05)。结论:固肾解毒汤联合西医常规治疗 终末期肾病血液透析患者的临床疗效较好,可以减轻临床症状,改善肾功能及微炎症反应,还可有效改善预 后,延长患者生存时间。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Gushen Jiedu Decoction combined with conventional western medicine therapy for hemodialysis patients with end- stage renal disease. Methods: A total of 110 cases of hemodialysis patients with end- stage renal disease were selected as the study objects and divided into the study group and the control group according to the random number table method,with 55 cases in each group. The control group was treated with conventional western medicine treatment, and the study group was additionally treated with Gushen Jiedu Decoction based on the treatment of the control group. Both groups were treated for 3 months. Clinical effects in the two groups were evaluated. Traditional Chinese medicine (TCM) syndrome scores,kidney function,microinflammatory reactions,and prognosis were compared between the two groups. Results:The total effective rate was 89.09% in the study group and 74.55% in the control group, the difference being significant (P<0.05). After treatment, TCM syndrome scores in the two groups were decreased when compared with those before treatment (P<0.05),and each TCM syndrome score in the study group was lower than that in the control group (P<0.05). After treatment,blood creatinine (SCr) and urea nitrogen (BUN) in the two groups were decreased when compared with those before treatment (P<0.05), and SCr and BUN in the study group were lower than those in the control group (P<0.05). After treatment,the levels of interleukin-6 (IL- 6) and tumor necrosis factor-α (TNF-α) in serum in the two groups were decreased when compared with those before treatment (P<0.05), and the levels of IL- 6 and TNF- α in serum in the study group were lower than those in the control group (P<0.05). The one-year survival rate in the study group was 87.76%, and the mortality rate was 12.24%;the one-year survival rate and mortality rate in the control group were 70.73% and 29.27% respectively. There was significant difference in one-year survival and mortality rates between the two groups (P<0.05). Conclusion: Gushen Jiedu Decoction combined with conventional western medicine therapy has good clinical effects in the treatment of hemodialysis patients with endstage renal disease, which can relieve clinical symptoms, improve kidney function, microinflammatory reactions,and prognosis,and extend their survival time.

    参考文献
    相似文献
    引证文献
引用本文

李红帅,徐菲,秦雪娟.固肾解毒汤联合西医常规治疗终末期肾病临床研究[J].新中医,2024,56(3):54-58

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-02-23
  • 出版日期:
文章二维码